5月9日，塞力医疗今日收盘10.97元，下跌4.94%，最新市净率2.47，总市值20.95亿元。 股东方面，截至2025年3月31日，塞力医疗股东户数46600户，较上次增加16035户，户均持股市值35.28 万元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入2.87亿元，同比-40.75%；净利润-14320949.69 元，同比-553.66%，销售毛利率23.60%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-9.24-10.012.4720.95亿行业平均 36.7828.221.80107.38亿行业中值27.4324.131.3158.16亿1漱玉平民-26.84-24.692.4246.62亿3海王生 物-5.04-5.113.3661.04亿4柳药集团8.268.030.8968.68亿5九州通8.9010.440.99261.70亿6鹭燕医药 9.539.180.9831.74亿7英特集团10.6410.521.1855.27亿8国药股份11.2411.231.28224.69亿9南京医药 11.3811.750.9667.04 ...

Group 1 - The core viewpoint of the news is that a comprehensive financial policy package has been introduced to support the stability of the market and expectations, particularly benefiting the elderly care sector [1][3] - The People's Bank of China has established a 500 billion yuan service consumption and elderly care relending tool to enhance financial support for key areas such as elderly care and service consumption [3] - The elderly care industry in China is projected to reach a scale of 9 trillion yuan in 2022, with expectations to exceed 12 trillion yuan by 2025, indicating a significant growth phase ahead [4][5] Group 2 - The elderly care concept stocks have shown strong performance, with multiple stocks such as Jinming Precision Machinery and Xinhua Jin experiencing significant price increases, some reaching the daily limit [2] - The new policy tool is an expansion and upgrade of the previous inclusive elderly care relending policy, which had a smaller quota of 40 billion yuan and was initially piloted [3] - The silver economy is expected to grow substantially, with projections indicating it could reach 30 trillion yuan by 2035, accounting for 10% of GDP, driven by various sectors including elderly services and health care [4]

Core Viewpoint - The company, Sealy Medical Technology Group Co., Ltd., has received a corrective order from the Hubei Regulatory Bureau of the China Securities Regulatory Commission, requiring it to rectify issues related to the mismanagement of raised funds and non-compliance with disclosure regulations [1][2]. Group 1: Company Issues and Rectification - The company failed to repay temporarily used raised funds of 82 million yuan, 374 million yuan, and 50 million yuan on the specified dates, leading to discrepancies in disclosed information regarding the usage period of these funds [2][3]. - The company's actions violated regulatory requirements concerning the management and use of raised funds and information disclosure [3]. Group 2: Rectification Measures - The company is actively seeking funds through various means, including enhancing accounts receivable collection, expanding business scale, and selling equity assets, to repay the raised funds as soon as possible [4]. - The company will strengthen financial planning to ensure that the raised funds are only used for operations related to its main business and will enhance fund management to resolve repayment issues promptly [5]. - The company has organized training for its board members and management to improve compliance awareness regarding the management and use of raised funds, and it will actively disclose the progress of fund repayment [6][7]. Group 3: Completion Timeline and Responsibilities - The company aims to fully repay the outstanding raised funds by the end of June 2025 [7]. - The responsibility for rectification lies with the chairman, general manager, financial director, board secretary, finance department, and securities department [8]. Group 4: Summary of Rectification - The company will enhance communication with regulatory authorities and implement corrective measures to protect investor rights, improve internal control systems, and ensure high-quality sustainable development [9].

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-039 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于湖北证监局对公司出具责令改正措施决定的整改报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 塞力斯医疗科技集团股份有限公司（以下简称"公司"或"塞力医疗"）于 2025年4月1日收到中国证券监督管理委员会湖北监管局出具的《关于对塞力斯医 疗科技集团股份有限公司、温伟、王政、沈燕采取出具责令改正措施的决定》 （[2025]22号）（以下简称"决定书"）原件，要求公司对《决定书》中指出的 事项进行整改，相关内容详见公司2025年4月2日披露于上海证券交易所网站 （www.sse.com.cn）的《关于收到湖北证监局责令改正措施决定的公告》（公告 编号：2025-027）。 收到上述《决定书》后，公司高度重视，立即向公司全体董事、监事、高级 管理人员及相关部门人员进行了通报与传达，并对《决定书》中涉及的问题进 ...

Core Viewpoint - The A-share smart medical sector experienced significant upward movement in the afternoon, with several companies reaching their daily limit up [1] Company Performance - Saily Medical and Runda Medical both hit the daily limit up, indicating strong investor interest and positive market sentiment [1] - Hongbo Co., Ltd. previously reached the daily limit up, showcasing a trend of rising stock prices within the sector [1] - Hongjing Technology, Chuangye Huikang, and Taikang Medical all saw their stock prices increase by over 8%, further highlighting the sector's robust performance [1]

Group 1 - The smart medical sector experienced a significant rally in the afternoon, with notable stocks such as Saili Medical (603716) and Runda Medical (603108) hitting the daily limit up [1] - Other companies in the sector, including Hongbo Pharmaceutical (301230), Mingde Biological (002932), and Kangtai Medical (300869), also saw increases in their stock prices [1] - The market trend suggests a strategy of buying index ETFs to capitalize on the rebound in leading companies within the sector [1]

审计报告 众环审字(2025) 0102901 号 塞力斯医疗科技集团股份有限公司全体股东: 一、审计意见 我们审计了塞力斯医疗科技集团股份有限公司(以下简称"塞力医疗公司")财务报表, 包括 2024年 12月 31 日的合并及公司资产负债表,2024年度的合并及公司利润表、合并及 公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 塞力医疗公司 2024年12月31日合并及公司的财务状况以及 2024年度合并及公司的经营成 果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则,我们独立于塞力医疗公司,并履行了职业道德方面的其他责任。我们相信,我 们获取的审计证据是充分、适当的,为发表审计意见提供了基础。 三、关键审计事项 关键审计事项是我们根据职业判断,认为对本期财务报表审计最为重要的事项。这些事 项的应对以对财务报表整体进行审计并形成审计意见为背景,我们不对这 ...

关于塞力斯医疗科技集团股份有限公司 2024 年度营业收入扣除情况表 的专项核查报告 众环审字（2025）0100973 号 同公厕套街划团集选择良刻设计巷干关 表资者组成人刘业营更好 N80S ty an 出非查对对于Bar n | Electoorn (asos) 中国社) | t a local 于塞力斯医疗科技集团股份有限公司 2024 年度营业收入扣除情况表 的专项核查报告 众环专字(2025) 0100973 号 塞力斯医疗科技集团股份有限公司全体股东: 我们接受委托,在审计了塞力斯医疗科技集团股份有限公司(以下简称"塞力医疗公司") 2024年 12月 31 日的合并及公司的资产负债表,2024年度合并及公司的利润表、合并及公 司的现金流量表和合并及公司的股东权益变动表以及财务报表附注(以下简称"2024 年度财 务报表"）的基础上,对后附的《塞力斯医疗科技集团股份有限公司 2024年度营业收入扣除 情况表》（以下简称"营业收入扣除表"）进行了专项核查。 按照《上海证券交易所股票上市规则》及《上海证券交易所上市公司自律监管指南第 2 号 -- 业务办理》的规定,编制和披露营业收入扣除表,提供真实 ...

众环审字(2025) 0102902 号 塞力斯医疗科技集团股份有限公司 内部控制审计报告 = 恒公到市公里因此或使得出新闻出 t and and a station of the country of the county of the count re and 内部控制审计报告 众坏审字(2025) 0102902 号 塞力斯医疗科技集团股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了塞 力斯医疗科技集团股份有限公司 (以下简称"塞力医疗公司")2024 年 12 月 31 日的财务报 告内部控制的有效性。 一、塞力医疗公司对内部控制的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 审计报告第1页共2页 日 CHA ...